Skip to main content
Premium Trial:

Request an Annual Quote

Tepnel Completes Orchid Dx Acquisition; Final Price Falls by $800K

NEW YORK, Jan. 22 (GenomeWeb News) - Tepnel has completed its acquisition of Orchid Biosciences' diagnostics unit, the companies said today.


However, "changing market conditions" caused Tepnel to shed around $800,000 off the original purchase price, dropping to $3.5 million from $4.3 million the final price that Tepnel paid for the division, the companies said.

Announced in October 2003, the deal called for Tepnel to acquire the product and services business of Orchid Diagnostics facilities in the United States, the United Kingdom, and Belgium. The purchase included the division's LifeMatch system and consumable product line for HLA testing and Orchid's Elucigene product line for testing certain genetic diseases, as well as certain liabilities.


Tepnel has taken control of the facilities formerly occupied by Orchid's diagnostic unit in Stamford, Conn., which will now be called Tepnel Lifecodes, and in Brussels, Belgium, which will now be called Tepnel Diagnostics. Tepnel officials said they intend to retain all of Orchid Diagnostics' employees.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.